What is MS Phase 3 Study Fingolimod FREEDOMS II?
CATEGORY:
TYPES:Generic: Fingolimod Clinical Trial
NCT00355134 is a 24-month double-blind, randomized, study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. Other study names are ID#CFTY720D2309 and FREEDOMS II.
Save up to 80% off your prescriptions!
How do members experience MS Phase 3 Study Fingolimod FREEDOMS II?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 1 | 2 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Flatulence | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 0 | |
| Mild | 1 | |
| None | 2 |
Member evaluations
AK_Drifter
evaluated on Jan 24, 2011
- Perceived effectiveness for transplant rejection prevention: Can't tell
- Side effects: None
Learn more about our community’s experience with MS Phase 3 Study Fingolimod FREEDOMS II
What are people saying about MS Phase 3 Study Fingolimod FREEDOMS II?
5
5
members have reported taking MS Phase 3 Study Fingolimod FREEDOMS II
Join the conversation and connect with people who have taken MS Phase 3 Study Fingolimod FREEDOMS II
Last updated: